Therapy of pruritus associated with skin diseases with the serotonin receptor antagonist ondansetron;Behandlung von pruritus als symptom von hauterkrankungen mit dem serotonin-rezeptorantagonisten ondansetron

JDDG - Journal of the German Society of Dermatology

Volumn 1, Issue 9, 2003, Pages 705-710

  Zenker, Sabine ^b   Schuh, Theda ^b   Degitz, Klaus ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b NONE

Author keywords

Ondansetron; Prurigo; Visual analogue scale

Indexed keywords

CAPSAICIN; NALMEFENE; NALTREXONE; ONDANSETRON; OPIATE ANTAGONIST; PLACEBO; SEROTONIN ANTAGONIST;

AGED; ARTICLE; ATOPIC DERMATITIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECZEMA; FEMALE; GASTROINTESTINAL TOXICITY; HEMODIALYSIS; HUMAN; MALE; PAPULAR URTICARIA; PARAPSORIASIS; PHOTOTHERAPY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROTONINERGIC SYSTEM; SIDE EFFECT; SKIN DISEASE; SYMPTOMATOLOGY; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTIPRURITICS; DERMATITIS, ATOPIC; ECZEMA; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; ONDANSETRON; PARAPSORIASIS; PRURITUS; SKIN DISEASES; TIME FACTORS; TREATMENT OUTCOME; URTICARIA;

EID: 0141447716     PISSN: 16100379     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1610-0387.2003.03731.x     Document Type: Article

References (16)

1. Ständer S, Weisshaar E, Steinhoff M, Luger TA, Metze D. Pruritus - Pathophysiologie, Klinik und Therapie Eine Übersicht. JDDG 2003; 1: 105-118.
2. Gollnick H, Weisshaar E. Pruritus: Pathogenese, Klinik und Entwicklung in der Therapie. In: Plewig G, Degitz K: Fortschritte der Praktischen Dermatologie und Venerologie 17. Berlin: Springer, 2000: 3-14.
3. Weisshaar E, Ziethen B, Gollnick H. Can a serotonin type 3 (5-HT3) receptor anatagonist reduce experimentally-induced itch? Inflamm Res 1997; 46: 412-416.
4. Downs AMR, Kennedy CTC. Successful treatment of intractable palmoplantar pruritus with ondansetron. Arch Dermatol 1998; 134: 925-926.
5. Schworer H, Hartmann H, Ramadori G. Relief of cholestatic pruritus by a novel class of drugs: 5-hydroxytryptamine type 3 (5-HT3) receptor antagonists: effectiveness of ondansetron. Pain 1995; 61: 33-37.
6. Müller C, Pongratz S, Pidlich J, Penner E, Kaider A, Schemper M, Raderer M, Scheithauer W, Ferenci P. Treatment of pruritus in chronic liver disease with the 5-hydroxytryptamine receptor type 3 antagonist ondansetron: a randomized, placebo-controlled, double-blind cross-over trial. Eur J Gastroenterol Hepatol 1998; 10: 865-870.
7. Ashmore SD, Jones CH, Newstead CG, Daly MJ, Chrystyn H. Ondanstron therapy for uremic pruritus in hemodialysis patients. Am J Kidney Dis 2000; 35: 827-831.
8. Murphy M, Reaich D, Pai P, Finn P, Carmichael AJ. A randomized, placebo-controlled, double-blind trial of ondansetron in renal itch. Br J Dermatol 2003; 148: 314-317.
9. Albares MP, Betlloch I, Guijarro J, Vergara G, Pascual JCP, Botella R. Severe pruritus in a haemodialysed patient: dramatic improvement with granisetron. Br J Dermatol 2003; 148: 376-377.
10. Wassilew SW. Serotoninantagonisten bei Pruritus. In: Plewig G, Degitz K: Fortschritte der Praktischen Dermatologie und Venerologie 17. Berlin: Springer, 2000: 437-440.
11. Kyriakides K, Hussain SK, Hobbs GJ. Management of opioid-induced pruritus: a role for 5-HT3 antagonists? Br J Anaesth 1999; 82: 439-441.
12. Borgeat A, Stirnemann HR. Ondansetron is effective to treat spinal or epidural morphine-induced pruritus. Anesthesiol 1999; 90: 432-436.
13. Gurkan Y, Tokder K. Prophylactic ondansetron reduces the incidence of intrathecal fentanyl-induced pruritus. Anesth Analg 2002; 95: 1763-1766.
14. Merze D, Reimann S, Beissert S, Luger T. Efficacy and safety of naltrexone, an oral opiate receptor antagonist, in the treatment of pruritus in internal and dermatological diseases. J Am Acad Dermatol 1999; 41: 533-539.
15. Bergasa NV, Alling DW, Talbot TL, Wells MC, Jones EA. Oral nalmefene therapy reduces scratching activity due to the pruritus of cholestasis: a controlled study. J Am Acad Dermatol 1999; 41: 431-434.
16. Reimann S, Luger T, Metze D. Topische Anwendung von Capsaicin in der Dermatologie zur Therapie von Juckreiz und Schmerz. Hautarzt 2000; 51: 164-172.